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Colonoscopies are often performed in children for diagnostic and therapeutic purposes. Our study compared two bowel-cleansing
solutions: sodium picosulphate, magnesium oxide, and citric acid (Pico-Salax) with liquid magnesium citrate as preparations for
colonoscopy. A retrospective chart review of all patients seen in the Gastroenterology outpatient clinic and who underwent bowel
cleansing in preparation for colonoscopy from February to December 2006 was undertaken. Thirty-two children received Pico-
Salax and 36 received liquid magnesium citrate. The tolerability of both solutions was similar. Most children in both groups had
liquidstoolsandcompletecolonoscopies.BowelpreparationforacolonoscopycanbesuccessfullyachievedusingeitherPico-Salax
or liquid magnesium citrate.
Copyright © 2009 Carolina Jimenez-Rivera et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
Examination of the lower gastrointestinal tract by
colonoscopy is often required in the pediatric age not
only for diagnostic but also for therapeutic purposes [1].
There are situations when endoscopists are unable to
perform complete colonoscopies due to inadequate bowel
cleansing, which is particularly challenging for pediatric
patients. Typically, children at our institution undergo a
2-day preparation, which includes the use of laxative agents
(Pico-Salax or magnesium citrate) and a clear ﬂuid diet. In
some cases children undergo nasogastric tube lavage with a
solution containing polyethylene glycol-electrolyte, however
this requires a hospital admission which increases the cost of
the procedure [2].
We compared two bowel-cleansing preparations in an
outpatient setting with children undergoing colonoscopies;
our primary outcome was to compare the eﬃcacy of
the cleansing for endoscopy. Secondary outcomes were to
compare tolerability and stool consistency between the two
groups.
2.MaterialsandMethods
A retrospective chart review was completed for all patients
seen in the Gastroenterology outpatient clinic who under-
went bowel cleansing in preparation for a colonoscopy from
February to December 2006 at the Children’s Hospital of
Eastern Ontario.
The clinic nurses assigned each patient one of the two
bowel preparations used in the outpatient clinic setting
at their discretion. One preparation contained magnesium
oxide, citric acid with sodium picosulphate (Pico-Salax,
Ferring Pharmaceuticals Inc., Canada). This powder consists
of sodium picosulphate 10mg, magnesium oxide 3.5g, and
citric acid 12.0g per sachet. Magnesium oxide and citric
acid form magnesium citrate (when dissolved in water)
and is administered as follows (per the manufacturer’s
recommendations): children from 1 to 6 years of age used
1/4 sachet, those from 6 to 12 years took 1/2 sachet and those
from 12 to 18 years used 1 sachet of Pico-Salax once per
day for two consecutive days. Liquid magnesium citrate was
administered at a dose of 60mL (1.74g of magnesium citrate2 Gastroenterology Research and Practice
Table 1: Patient characteristics.
Overall Pico-Salax Magnesium
citrate P value
Total N 68 32 36 —
Age years,
mean (SD) 11.63 (3.88) 13.01 (3.09) 10.40 (4.13) .0042
Gender, N
(%) of male 37 (54.4) 15 (46.9) 22 (61.1) .35
per30mL)inchildrenbetween10to15kg,90mLinchildren
between 16 and 20kg, 150mL in children between 21 to
35kg,and300mLinchildren>36kgalsofortwoconsecutive
days. Additional measures included the administration of
bisacodyl at a dose of 15mg in children >20–35kg or age 6–
12 years of age and 20mg in children >36kg or 12–18 years
of age following Pico-Salax or magnesium citrate. Castor oil
(15–30mL) was given to children younger than 6 years of
age. Children remained on a clear liquid diet for the two days
prior to the procedure.
Physiciansrecordedsuccessofbowelpreparationsystem-
atically including ease of endoscopy classiﬁed by need of irri-
gation and suctioning, minimal suctioning, or completion
of procedure without irrigation and/or suctioning. Ease of
endoscopy was considered excellent when there was minimal
suctioning or there was no need of irrigation or suctioning.
Tolerability was assessed by the recording of complaints such
as vomiting, cramping and abdominal pain.
Statistical analyses were performed using R software
(V2.7.2).Two-sidedP-valuesoflessthan.05wereconsidered
statistically signiﬁcant. Continuous variables were sum-
marized using mean and standard deviations. Categorical
variables were summarized using frequency and percentage.
Logistic regression was performed to compare the odds of
primary outcome (excellent outcome) between the Pico-
Salax and magnesium citrate groups with and without
controlling for age. The rate of excellent outcome in children
under age 6 and above age 6 was compared using Fisher’s
exact test. Secondary outcomes (tolerability and stool type)
were also compared between the two groups using Fisher’s
exact test.
3. Results
A total of 68 children were included in the study, 32 received
Pico-Salax and 36 received magnesium citrate. Mean age was
11.6 ± 3.9 years. Of the total of 68 candidates, 37 (54.4%)
were males. Patient characteristics are reported in Table 1.
Mean age was signiﬁcantly diﬀerent between the two
groups (P = .0042). Only 3.1% (1/32) of children that
received Pico-Salax were under age 6, whereas 22.2% (8/36)
of children that received magnesium citrate were under
age 6. Therefore, Pico-Salax was more likely to be used
on older children whereas magnesium citrate was preferred
for use on younger children. Fifty-nine percent (19/32) of
children in the Pico-Salax group and 52.8% (19/36) of the
magnesiumcitrategrouphadexcellentoutcome(OR = 1.31,
95%CI 0.5–3.4, P = .59) (Table 2). The logistic regression
analysis controlling for age estimated that the odds ratio
of having excellent outcome between the Pico-Salax group
and magnesium citrate group was 1.50 (95%CI, 0.54–4.20,
P = .44). Therefore, there was no statistically signiﬁcant
evidence that the odds of excellent outcome were diﬀerent
between the two bowel-cleansing solutions.
The percentage of excellent outcome between children
less than 6 years of age and above 6 years was also compared.
It was found that 55.6% (5/9) of children under age 6 had
excellent outcome and 55.9% (33/59) of children above age
6h a de x c e l l e n to u t c o m e( P = 1.00). Therefore, there was
no statistically signiﬁcant evidence that the percentage of
excellent outcome was diﬀerent between children less than
6 years and above age 6.
Tolerability of both cleansing agents was similar as
evidenced by lack of diﬀerence in adverse events (vomiting,
cramping,andpain),andmostpatientshavingnosymptoms
to report (Table 3). The magnesium group tended to have
more liquid stools than the Pico-Salax group as reported
in Table 3. However, this diﬀerence did not reach 0.05
signiﬁcance level. There were more liquid stools in the
magnesium citrate group compared to Pico-Salax, so there
appears to be an oﬀset of adverse events compared to
ﬁrmness of stool.
The percentage of complete colonoscopy was 97% in
the Pico-Salax group and 92.7% in the magnesium citrate
group.Thereweretwopatients(oneineachgroup)onwhom
complete colonoscopy could not be performed due to the
presence of formed stools; these patients were eventually
admitted to hospital for nasogastric tube lavage with Golitely
(Polyethylene glycol 3350 and electrolyte solution).
4. Discussion
Adequate bowel preparation is crucial for a successful
colonoscopy. This can be signiﬁcantly challenging in the
pediatric population, as acceptance and tolerability of avail-
able agents might be poor.
Two bowel preparation protocols are available at our
center (Pico-Salax and liquid magnesium citrate), and used
in combination with either bisacodyl or castor oil. Interest-
ingly, there were no signiﬁcant diﬀerences found between
Pico-Salax and magnesium citrate in our study. Tolerabilility
and eﬃcacy of both methods were similar; this could be
explained by the presence of magnesium citrate (an osmotic
agent)in both solutions asthe mainingredient. Theaddition
of sodium picosulphate (a contact laxative that stimulates
smooth muscle contraction) to magnesium oxide and citric
acid (that forms magnesium citrate when dissolved in water)
did not reveal higher beneﬁts in our patient population.
One of the limitations of the present study is potential
imbalance in other clinical parameters (such as age) between
the two groups. This imbalance could confound the eﬀect
of bowel preparation methods on the bowel preperation
outcome. Young children are the most diﬃcult to prepare
for a colonoscopy. We compared outcomes in children less
than6yearstochildrenabove6yearsandfoundnodiﬀerence
between the ease of endoscopy or tolerability of the cleansingGastroenterology Research and Practice 3
Table 2: Comparison of ease of colonoscopy between Pico-Salax and magnesium citrate.
Pico-Salax Magnesium
Cruel odds ratio of ease of
endoscopy
(Pico-Salax/Magnesium)
95% CI for the
cruel odds ratio
P-value
EO
† N (%) 19 (59.4) 19 (52.8) 1.31 0.50, 3.42 .59
†EO: Excellent outcome is minimal or no need for irrigation and/or suctioning.
Table 3: Comparison of tolerability and stool type between Pico-
Salax and magnesium citrate.
Pico-Salax
(N = 32)
Magnesium citrate
(N = 36)
P-value
∗
Adverse events†
(N,% ) 1 (3.1) 4 (11.1) .36
No symptoms 31 (96.9) 32 (88.9)
Stool present
Formed stool
(hard, soft) 8 (25) 3 (8.3) .098
Liquid 24 (75) 33 (91.7)
∗Fisher’s exact test, †Adverse events were vomiting, cramping, and abdomi-
nal pain.
agent. This could be related to the small cohort in our study;
900 subjects would need to be included to detect a signiﬁcant
diﬀerence with 80% power.
One would assume that older children’s bowel prepa-
ration would be of better quality than younger children’s,
however this was not the case in our study. One could
speculate that older children may not have been entirely
compliant by taking the laxative agent or that the diet was
not fully followed, as older children might have had less
supervision.
There are controversies regarding the best combination
of laxatives as well as the need for dietary restrictions.
Abubakar et al. [3] stated that the use of oral bisacodyl for
two consecutive days prior to the procedure and a phosphate
enema the morning of the procedure provided excellent
bowel preparation, these children did not follow any dietary
restrictions.
On the other hand, Dahshan et al. [4] concluded that
the2-daybisacodylpreparationyieldedpoorbowelcleansing
as compared to either two Golytely or a combination of
magnesium citrate and X-prep (senna fruit, sugar, and 7%
alcohol).
Others believe that dietary restriction is a limiting factor
for successful bowel cleansing and particularly in children.
El-Baba et al. [5] showed that the administration of a
prepackaged diet kit (low residue solid and liquid food kit)
in combination with magnesium citrate and bisacodyl the
daybeforetheprocedurewasmoreeﬀectivethanoralsodium
phosphate and liquid diet in preparation for colonoscopy.
Other methods of bowel cleansing, such as the oral
administration of sodium phosphate solution proved a
higher risk for electrolyte disturbances particularly hyper-
phosphatemia,hypocalcemia,andhypokalemiainupto57%
of adult patients [6, 7] and could be suspected to also be
problematic in children and youth.
Polyethylene glycol-electrolyte containing solutions are
highly eﬃcient in preparation for colonoscopy in children
[4, 8], the limitation of this modality for bowel cleansing
is the large volume required to achieve adequate results.
Furthermore, most children are unable to take this solution
orally and need to be admitted to hospital for nasogastric
tube lavage, which can be inconvenient and more expensive.
Pico-Salax has been shown to have a high eﬃcacy and
safety in adults as a method of preparation for colonoscopies
[9–13]. Pinﬁeld and Stringer [14] described the eﬃcacy of
Pico-Salax in a pediatric randomized study that compared
it to bisacodyl. All children (N = 32) on Pico-Salax were
reported to have good or excellent preparation and fewer
episodes of abdominal pain than in the group with bisacodyl
administered. In our study, symptoms of abdominal pain
or vomiting were low, with both groups having similar
tolerability rates.
T h eh i g he ﬃcacy of magnesium citrate as a cleansing
agent in adults was reported by Chen et al. [15]w h e r em a g -
nesium citrate in combination with bisacodyl was tolerated
better and was more eﬀective than castor oil. Magnesium
citrate provided the day before the colonoscopy proved
more eﬃcacious than oral sodium phosphate in adults [16].
Most recently Sabri et al. [17] compared magnesium citrate
and oral sodium phosphate showing similar tolerability
and eﬃcacy in adolescents. In the present study we used
magnesium citrate in combination with bisacodyl or castor
oil with good results that were similar to the use of Pico-
Salax.
In summary, comparison of the two available bowel
preparations showed no signiﬁcant diﬀerence with regards
to ease of endoscopy and tolerability. Colonoscopy with
minimal or no need for irrigation and/or suctioning was
achieved in about half of the patients on each group with the
rest needing some intervention by the colonoscopist leading
toachievingsuccessfulcompletecolonoscopyinthemajority
of patients. The retrospective nature of the study and the
small study cohort represent potential limitations and larger
studies may be warranted.
Appendix
See Tables 1, 2,a n d3
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